

KERYX BIOPHARMACEUTICALS INC
 Form 3
 March 17, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Adams Brian</p> <p>(Last) (First) (Middle)</p> <p>C/O KERYX BIOPHARMACEUTICALS, INC.,Â 750 LEXINGTON AVENUE</p> <p>(Street)</p> <p>NEW YORK,Â NYÂ 10022</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>03/10/2015</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>KERYX BIOPHARMACEUTICALS INC [KERX]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) General Counsel</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p>
--	---	---	--	---	--

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock (Restricted)	40,000 ⁽¹⁾	D	Â
Common Stock (Restricted)	23,875 ⁽²⁾	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options (Right to Buy)	04/14/2015 ⁽³⁾	04/14/2024	Common Stock	60,000	\$ 14.06	D	Â
Stock Options (Right to Buy)	01/04/2016 ⁽⁴⁾	01/04/2025	Common Stock	47,750	\$ 14.34	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Adams Brian C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK, NY 10022	Â	Â	Â General Counsel	Â

Signatures

/s/ James F. Oliviero, 03/16/2015
Attorney-in-Fact

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The 40,000 shares are restricted common stock, with one-third of the 40,000 shares vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017 and April 14, 2017.

(2) The 23,875 shares are restricted common stock, with one-third of the 23,875 shares vesting on January 4, 2016, and one-twelfth vesting on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.

(3) The options vest according to the following schedule: one-third of the 60,000 options vesting on April 14, 2015, and one-twelfth vesting on each of July 14, 2015, October 14, 2015, January 14, 2016, April 14, 2016, July 14, 2016, October 14, 2016, January 14, 2017 and April 14, 2017.

(4) The options vest according to the following schedule: one-third of the 47,750 options will vest on January 4, 2016, and one-twelfth will vest on each of April 4, 2016, July 4, 2016, October 4, 2016, January 4, 2017, April 4, 2017, July 4, 2017, October 4, 2017, and January 4, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.